Rapid Hemostasis in a Sheep Model Using Particles That Propel Thrombin and Tranexamic Acid

James R. Baylis, BSc; Andres Finkelstein-Kulka, MD; Luis Macias-Valle, MD; Jamil Manji, MSc; Michael Lee, BSc; Elina Levchenko, BSc(c); Christopher Okpaleke, MPH; Salahuddin Al-Salihi, MD; Amin Javer, MD; Christian J. Kastrup, PhD

**Objectives/Hypothesis:** Bleeding during endoscopic sinus surgery and open surgeries can easily obstruct the surgeons’ field of view and increase morbidity and risk of intraoperative complications. Intraoperative bleeding could potentially be addressed by a hemostatic agent that safely disperses itself through the escaping blood. We tested the safety and efficacy of a self-propelling formulation of thrombin and tranexamic acid (SPTT) in stopping bleeding in a paranasal sinus injury and in an open surgical carotid injury sheep model.

**Study Design:** Interventional animal study.

**Methods:** SPTT was tested in the sinonasal space following endoscopic injury to the inferior turbinate of six sheep, and to the common carotid artery following open surgical injury in eight sheep. In the nasal cavity, bleeding time and local inflammation were measured and compared to plain gauze. Following carotid arteriotomy, successful hemostasis and markers of thrombosis and coagulopathy were compared to Floseal.

**Results:** SPTT significantly decreased bleeding times in the sinonasal space compared to plain gauze (mean difference = 3.8 minutes, *P* = .002). All of the carotid bleeds (100%) were successfully controlled with SPTT after 10 minutes of application under pressure, compared to 25% with Floseal. No adverse events were noted, and there was no evidence of thromboembolism.

**Conclusions:** SPTT significantly reduced bleeding time in a sheep model of surgical sinus bleeding and successfully stopped bleeding following catastrophic carotid artery injury, with no adverse events observed.

**Key Words:** Functional endoscopic sinus surgery, hemostat, intraoperative bleeding, catastrophic bleeding, calcium carbonate, fibrinolysis.

**Level of Evidence:** NA

**INTRODUCTION**

Poorly controlled intraoperative bleeding can lead to complications such as infection, procedural error, increased operating time, blood product transfusion, and death. In endoscopic surgery, intraoperative bleeding is especially problematic, given the narrow field of view; even moderate bleeding can sufficiently obstruct the surgical field. Intraoperative bleeding during functional endoscopic sinus surgery (FESS) can be reduced by perioperative measures, including preoperative corticosteroids, controlled hypotension, the reverse Trendelenburg position, vasoconstrictors, and warm saline irrigation. However, these techniques are limited and not suited for managing acute severe bleeding.

When inadvertent injury to the internal carotid artery, anterior or posterior ethmoid, or sphenopalatine artery occurs during FESS, management must be swift, as the patient can decompensate within minutes. Immediate tamponade with nasal packing can be applied in these scenarios, but this is associated with high morbidity and mortality if the ruptured vessel becomes stenosed or occluded. Electrocauterization can also be effective, but is associated with severe unfavorable tissue reactions. Recently, more powerful topical hemostatic agents such as Floseal matrix containing thrombin (Baxter International, Deerfield, IL), Surgicel (Ethicon; Johnson & Johnson, New Brunswick, NJ), chitosan gel, fibrin-based products, and muscle patches have been proposed as effective interventions with fewer adverse
events.\textsuperscript{13,14} Fortunately, such bleeds are rare, occurring in approximately 1% of patients undergoing pituitary surgery, and more frequently in complex skull base procedures.\textsuperscript{15} Topical hemostatic agents that contain thrombin, which is an endogenous coagulation enzyme, have emerged at the forefront for management of catastrophic surgical bleeding as well as intractable epistaxis.\textsuperscript{13,16} One of these agents, Floseal, is known to worsen long-term surgical outcomes, such as by increasing granulation tissue and adhesions, but these are often considered acceptable losses in the context of severe bleeding scenarios.\textsuperscript{17,18} However, the applicabilities of these agents are inherently limited during FESS or during severe epistaxis. These topical agents are indicated only when bleeding sites can be visualized, which is often difficult.\textsuperscript{4} When blood loss is severe, conventional topical agents cannot reach the damaged vasculature due to the rapid outflow of blood. We hypothesize that a self-propelling hemostatic agent, which can move through flowing blood to the bleeding wounds, would be more effective than current static hemostatic strategies used in epistaxis, FESS, and cases of catastrophic bleeding.

We have developed a self-propelling hemostatic agent that vigorously effervesces upon contact with blood.\textsuperscript{19} This agent consists of calcium carbonate (CaCO\textsubscript{3}) microparticles, thrombin, and tranexamic acid (TXA), which is an antifibrinolytic agent that is administered systemically. When applied to a wound, CaCO\textsubscript{3} propels and disperses thrombin and TXA against flow, thereby improving contact with the bleeding vasculature. This propulsion significantly reduced blood loss in multiple in vivo and in vitro models of hemorrhage; for example, when formulated upon gauze, it significantly increased survival in a swine femoral artery bleeding model of fatal junctional hemorrhage in combat settings.\textsuperscript{19,20} Here, we tested to see whether this agent, a self-propelling formulation of thrombin and TXA (SPTT), is safe and effective in producing hemostasis in a sheep model of minor and major surgical bleeding.

**MATERIALS AND METHODS**

**Preparation of SPTT**

SPTT for application to turbinate injuries was prepared based on previously described methods.\textsuperscript{19} To adsorb CaCO\textsubscript{3} and thrombin onto gauze, 188 mg of CaCO\textsubscript{3} microparticles (American Elements, Los Angeles, CA), 188 µL glycine-buffered saline (GBS; 40 mM glycine, 171 mM NaCl, pH 7.2), and 0.34 mg human thrombin (specific activity = ~3,650 U/mg; Haematologic Technologies, Essex Junction, VT) were coencapsulated on ice for 20 minutes. Suspensions were diluted by addition of 188 µL GBS, and pipetted onto 2.5 × 2.5-cm\textsuperscript{2} pieces of Kerlix gauze (Covidien, Dublin, Ireland), which were then lyophilized. To load gauze with protonated TXA, 375 µL TXA solution (2 M, pH 4.3; Chem-Impex International, Wood Dale, IL) was applied to an equal amount of Kerlix gauze, which was then baked for 30 minutes at 120°C. CaCO\textsubscript{3}-thrombin gauze and TXA gauze were layered to form SPTT immediately prior to application to the turbinate.

SPTT for application to carotid injuries was prepared similarly; Kerlix gauze measuring 10 × 10 cm\textsuperscript{2} was loaded with 0.5 g CaCO\textsubscript{3} and 0.34 mg (1,250 IU) human thrombin, and a separate gauze of equal dimensions was loaded with 3.9 g of protonated TXA.

**Animal Preparation and Instrumentation**

All procedures involving animals were approved by the University of British Columbia Animal Care Committee (protocol #A14-0172) and performed according to Canadian Council on Animal Care guidelines. Dorset cross sheep (average body weight = 51 kg) were induced using 4 to 6 mg/kg of intravenous propofol. Animals were then intubated and maintained on isoflurane anesthesia (2%–5%). Ketoprofen (3 mg/kg) was given subcutaneously to manage postoperative pain, and an esophageal tube was placed to prevent bloat. Heart rate, electrocardiogram, noninvasive blood pressure, expired carbon dioxide, inspired and expired isoflurane, oxygen saturation, and temperature were monitored throughout all procedures.

**Initial Biopsy and Initiation of Hemorrhage**

Six sheep were included in this part of the study. Nasal cavities were explored with a 0° rigid endoscope, and inferior turbinates were identified. Using right- and left-angled 3-mm through-cutting Toffel punches (Access 11-371, 11-372), a turbinate biopsy/injury was performed in the medial aspect of the middle third (posterior injury). SPTT gauze or plain gauze, which was deidentified to the operator, was applied to the site of the injury for 60 seconds using Blakesley forceps. After gauze removal, bleeding was monitored endoscopically for 10 minutes. Neither gauze contained any other agents to reduce nasal trauma during gauze removal. Attempts to quantify volumetric blood loss were unsuccessful, as suction could not be applied concomitantly with compression and endoscopic visualization of the injury site. Additionally, it was not possible to quantify any blood that may have flowed posteriorly into the nasopharynx. This procedure was replicated to produce a posterior injury on the contralateral side. After bleeding from each posterior injury had abated, the posterior injury sites were covered with gauze to prevent anterograde flow of any SPTT residue. Following this, similar injuries were repeated anteriorly and placed 1 cm posterior to the head of the inferior turbinate (anterior injury). Four injuries were completed per animal, for a total of 24 injuries over six sheep. Following randomization of the first injury, the remaining three injuries were assigned such that each turbinate received both treatments, and treatment assignments on the contralateral turbinate were reversed anterior–posterior. Animals were recovered and monitored for 2 days.

To test whether SPTT was associated with any medium-term adverse events, four separate sheep were used. Bleeding was initiated and treated as described above, except that each turbinate received only one biopsy/injury (two total per sheep), and each sheep was treated with either SPTT containing 156 IU of thrombin or Floseal containing an equal dose of thrombin. Animals were recovered and monitored for 15 or 17 days for any changes to behavior or vital signs.

**Carotid Artery Injury**

Eight sheep were included in this part of the study. While anesthetized, a midline vertical neck incision was performed, and dissection was completed until identification of the strap muscles. The deep neck facial layers were followed until the right carotid sheath was identified. The common carotid artery was dissected away from surrounding tissues to obtain a minimum of 5 cm of artery exposure. The artery was clamped proximally and punctured using an 11-blade scalpel, to enable a
standard arteriotomy using a 4-mm endoscopic mushroom punch. Punch injuries are regularly used for testing the efficacy of hemostatic agents in large animal models of hemorrhage, although a linear vascular injury could have been used to cause even greater bleeding.\textsuperscript{21,22} Clamps were released to initiate bleeding. After 3 seconds of free bleeding and with the operator blinded, SPTT gauze or gauze containing Floseal with an equal amount of thrombin (1,250 IU) was directly applied to the puncture site. Plain gauze pack was mounted above the SPTT or Floseal gauze, and 36 N (8 lb) of force was applied for 10 minutes. Local pressure to the internal carotid is a maneuver clinically accepted in neck surgery and endoscopic procedures; however, the magnitude and direction of pressure may differ between clinical scenarios. Bleeding was assessed after 10 minutes by releasing pressure, and visualizing the injury without removal of the SPTT or Floseal gauze. If hemostasis was achieved, the final gauze was removed and recurrence of hemorrhage was recorded. Carotid arteries were then ligated and animals were euthanized by sodium pentobarbital overdose (120 mg/kg intravenously). Once again, bleeding volumes could not be accurately measured in this model due to the high pressure and projectile nature of the bleed, which flooded the surgical field rapidly after injury.

**Histology, Coagulation Analysis, and Necropsy**

Biopsies of turbinate injury sites at baseline and at 48 hours post-treatment were examined histologically. These images were scored by a blinded, certified pathologist for inflammation, ulceration, infiltrate, and inflammatory debris using the following scale: 0 = normal microscopic findings, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe. Blood was collected at baseline, 48 hours after turbinate injury, and approximately 20 minutes after carotid injury to measure semiquantitative fibrinogen concentration, D-dimer levels, hemoglobin, hematocrit, platelet count, prothrombin time (PT), and activated partial thromboplastin times (APTT). Following sacrifice, carotid arteries were excised and grossly examined for any vessel occlusion. Cadavers were necropsied, and brains, lungs, and hearts were grossly examined for ischemic or infarctive lesions.

**Statistical Analysis**

All statistical analyses were performed with Prism 5 (GraphPad Software, San Diego, CA). Bleeding times, pathologist scores, and coagulation parameters were compared by Mann-Whitney U test. When a group of baseline pathologist scores or semiquantitative fibrinogen concentrations were each the same value, comparisons were made with a Wilcoxon signed-rank test.

**RESULTS**

After turbinate injuries, sites receiving SPTT bled for 5.09 ± 2.25 minutes (mean ± standard error), compared to 8.21 ± 2.16 minutes for plain gauze sites (P = .002, Fig. 1B). Four of the 12 control sites did not achieve hemostasis within 10 minutes, whereas all SPTT sites did. To confirm that the location of turbinate injury did not significantly affect bleed times, anterior and posterior sites that had received the same treatment were compared. Anterior and posterior SPTT sites were not significantly different, bleeding for 5.32 ± 2.85 minutes and 4.85 ± 1.70 minutes, respectively (P = .76). Similarly, anterior and posterior control sites were not significantly different, bleeding for 7.94 ± 2.26 minutes and 8.47 ± 2.22 minutes, respectively (P = .43).

At baseline, all pathologist scores for ulceration, infiltration, inflammation, and inflammatory debris were 0 except for one inflammation score of 1 (Fig. 2). Two days after turbinate injury, mean scores for each parameter increased for SPTT and control sites; however, significant differences were only seen when comparing baseline inflammation with SPTT (P = .01) and baseline ulceration with control (P = .05; Table I). There were no significant differences in pathologist scores between SPTT sites and control sites.

Following carotid artery injury and compression, SPTT stopped bleeding in 100% (four of four) cases when dressings remained in place (Table II). When the dressings were fully removed, rebleeding occurred in 75% (three of four) of these injuries. Floseal stopped bleeding in 25% (one of four) injuries, and this injury did not

Laryngoscope 00: Month 2016

Fig. 1. Self-propelling formulation of thrombin and tranexamic acid (SPTT) decreases bleed times following turbinate injury. (A) Schematic showing SPTT-loaded gauze being applied paranasally and SPTT particles rapidly delivering cargo through blood flow. (B) Bleed times following turbinate injury and application of hemostatic agent. n = 12. *P < .01. Error bars represent standard error of the mean. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
bleed when the dressing was removed. In animals that did not achieve hemostasis following removal of dressings, bleeding was severe and not expected to halt without further intervention.

Baseline hemoglobin concentrations were 93 ± 6 mg/mL, hematocrits were 0.28 ± 0.02, and platelet counts were 266 ± 96 x10⁹/L (Fig. 3). PT and APTT were 13.7 ± 0.9 seconds and 35.5 ± 6.5 seconds, respectively. Semiquantitative fibrinogen concentration was 1.0 mg/mL for each sample. D-dimer concentrations were 176 ± 78.7 ng/mL (Fig. 4). Two days following turbinate injury, no parameter changed significantly except hemoglobin. Additionally, D-dimer levels did not differ significantly between any time points or between sheep that received SPTT or Floseal to their carotid injuries (P > .05).

No occluded vessels were found in any animal postmortem. No signs of thromboembolism or ischemia were found during gross inspection and histopathology of heart, brain, and lungs. No animal showed any major changes in behavior or vitals within 15 or 17 days following turbinate injury.

**DISCUSSION**

During FESS and cases of epistaxis, mild to moderate bleeding is common and can be managed easily without long-term sequelae; however, profuse blood loss can be very difficult to manage and could increase morbidity and mortality. Various hemostatic agents have been developed for sinus surgery and primary epistaxis, but blood flow pushes these agents away from the bleeding site, decreasing their contact times and their ability to form stable clots. The sheep model used here was a remarkable replication of the most relevant clinical bleeding events faced by rhinologists. The turbinate injury model accurately represents common FESS bleeding and primary epistaxis events, whereas the carotid bleed model reflects the most catastrophic scenarios. Both injuries were easily induced and highly reproducible, and

**TABLE I.**

<table>
<thead>
<tr>
<th>Probability Values Comparing Pathologist Scores of Turbinate Biopsies at Baseline and 2 Days After Injury Was Treated.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline vs. Control</td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>Inflammation</td>
</tr>
<tr>
<td>Ulceration</td>
</tr>
<tr>
<td>Infiltrate</td>
</tr>
<tr>
<td>Inflammatory debris</td>
</tr>
</tbody>
</table>

**TABLE II.**

<table>
<thead>
<tr>
<th>The Proportion of Carotid Artery Injuries That Achieved Hemostasis Within 10 Minutes of Treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dressing on Wound</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>SPTT FLOSEAL</td>
</tr>
<tr>
<td>Achieved hemostasis</td>
</tr>
</tbody>
</table>

*All pathologist scores are presented as mean ± standard error of the mean. n = 7–23. *P < .05. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]*

Fig. 2. Assessing self-propelling formulation of thrombin and tranexamic acid (SPTT)’s local tissue damage in the inferior turbinate following injury and treatment. (A) Representative histopathological images of turbinate epithelium at baseline and 2 days postinjury. Scale bar = 150 μm. (B–E) Pathologist scores for inflammation, ulceration, infiltrate, and inflammatory debris of turbinate biopsies 2 days postinjury. Error bars represent standard error of the mean. n = 7–23. *P < .05. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]*
Thus work is ongoing to validate this sheep model for research in FESS. In this study, we show that SPTT stopped both prolonged surgical epistaxis and massive carotid bleeding, and we detected no adverse events. Therefore, SPTT may become an invaluable agent to reduce bleeding and improve patient outcomes in a variety of FESS and difficult epistaxis scenarios where current treatments are slow or fail to achieve hemostasis.

In the turbinate injury model, SPTT significantly decreased and nearly halved bleeding times compared to controls that received only local pressure with plain gauze. In sinus surgery, SPTT could improve field of view to allow for more complete surgery while reducing operating time and incidence of complications associated with profuse and continued bleeding.

Treatment of turbinate injuries with SPTT did not cause any more local tissue damage than plain gauze alone, even without irrigation or use of corticosteroids. Some packing agents have been shown to increase granulation tissue and adhesions in patients, which require subsequent lysis. Specifically, gelatin-containing resorbable hemostatic agents, such as FloSeal and Gel foam (Pfizer, New York, NY), have been shown to worsen inflammation, elicit foreign body reactions, and cause fibrosis potentially leading to adhesions. Although some of these agents also contain thrombin, thrombin is suggested to be uninvolved in adhesion formation. Therefore, a thrombin-containing gelatin-free hemostatic agent, such as SPTT, which can achieve rapid hemostasis without causing increased inflammation, would be very desirable. However, further studies are required to determine how SPTT compares to other hemostatic agents regarding long-term sequelae relating to inflammation and healing, such as fibrosis or adhesions over months following application.

Powerful hemostatic agents, such as thrombin, carry risks of thrombosis, especially following application to major vessels such as carotid arteries. To determine whether SPTT caused thrombosis, systemic D-dimer concentrations were measured. D-dimer concentrations are measured to clinically rule out thrombosis. D-dimer levels that can rule out thrombosis have not been established for sheep; however, all concentrations measured here are within normal ranges for sheep, humans, and other laboratory animals, such as dogs. Furthermore, D-dimer concentrations at 48 hours after turbinate injury did not differ significantly from baseline, suggesting no incidence of thromboembolism.

Fig. 3. Hematological analysis of venous blood samples at presurgical baseline and 48 hours after turbinate injury and hemostatic treatment, including hemoglobin, hematocrit, platelet count, prothrombin time, activated partial thromboplastin time, and semi-quantitative fibrinogen. Error bars represent standard error of the mean. n = 5–6. SPTT = self-propelling formulation of thrombin and tranexamic acid. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]

Fig. 4. D-dimer concentrations in venous blood samples at baseline, 2 days following turbinate injury, and 20 to 30 minutes following carotid injury and hemostatic treatment. Error bars represent standard error of the mean. n = 3–6. SPTT = self-propelling formulation of thrombin and tranexamic acid. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
Similarly, of the other blood count parameters measured, only hemoglobin significantly differed between baseline and 48 hours post-application. No signs of pain or adverse events were observed up to 17 days after treatment. Together, these results suggest that no significant thrombotic events occurred and that the risk of thrombosis associated with paranasal application of SPTT is low. However, further preclinical studies involving larger numbers of animals are required to demonstrate this rigorously, and to translate this technology for use in humans.

In this model, SPTT also effectively stopped bleeding from the common carotid artery, which is a high-flow, high-pressure bleed that is a catastrophic complication of surgery. There have been conflicting reports regarding which hemostatic agent should be used in the event of an endoscopic carotid artery bleed. One study, which used a live sheep endoscopic carotid artery injury model, concluded that the U-clip and the muscle patch are superior to Floseal, oxidized regenerated cellulose, and chitosan gel. However, a systematic review that included different endoscopic and open surgical approaches showed that Floseal was superior in reducing blood loss. Given that our carotid injury model was an open approach, we chose to compare SPTT to Floseal. When clot disruption was avoided, by allowing the gauze to remain adhered to the bleeding site, SPTT achieved hemostasis in more sheep than Floseal. This strongly suggests that SPTT may be an effective clinical treatment of catastrophic intraoperative bleeding. However, further studies are required to demonstrate SPTT’s efficacy and superiority to clinical standards, such as the muscle patch, and to optimize SPTT’s formulation and method of application.

No signs of thromboembolism were seen by gross inspection or histopathology of heart, brain, and lungs in any animals treated with SPTT or Floseal. However, additional studies that investigate long-term embolic, thrombotic, or ischemic risks associated with using SPTT or Floseal. However, additional studies that investigate long-term embolic, thrombotic, or ischemic risks associated with using SPTT for major arterial bleeds are required. These studies are especially pertinent to test SPTT’s safety in carotid injuries, as the model presented here did not allow recovery of the animals or time for neurological deficits and secondary ischemic strokes to manifest.

CONCLUSION

This study has demonstrated that self-propelling thrombin- and TXA-loaded particles can effectively treat bleeding in an endoscopic sinus surgery and open carotid injury model. Following turbinate injury, SPTT achieved hemostasis significantly faster than standard gauze packing. There was no indication that SPTT caused any local tissue damage or systemic thrombosis. Moreover, SPTT remarkably stopped catastrophic bleeding following carotid artery injury and preliminary results suggest its efficacy is comparable or superior to clinical standards for managing severe bleeding. Although this self-propelled particle-based hemostatic agent was efficacious and did not have adverse effects in this model, further preclinical studies are required to fully understand its longer-term safety risks prior to clinical testing.

Acknowledgment

The authors thank J. H. Yeon, University of British Columbia (UBC) Animal Care Services, and the UBC Centre for Comparative Medicine for helpful suggestions.

BIBLIOGRAPHY


